Drugs / ELI-002 2P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04853017 | Oct 2021 → Jan 2023 | cholangiocarcinoma, colorectal cancer, gallbladder carcinoma, non-small cell lung carcinoma +2 | Elicio Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELI-002 2P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853017 ↗ |
| Modality | Vaccine | “Cancer vaccine ELI-002 2P” PMID 38195752 ↗ Jan 2024 |
| Route | Subcutaneous | “administered via SC injection weekly for 4 consecutive weeks” NCT04853017 ↗ |
| Target | KRAS | “lymph node-targeting amphiphile vaccination induces persistent T cell responses targeting oncogenic driver KRAS mutations” PMID 40790272 ↗ Aug 2025 |